Investigational drug · Phase 3
Apraglutide
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF), Short Bowel Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "Apraglutide"
First trial start
2021
Jul 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Apraglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Short Bowel Syndrome (SBS)
- SBS Associated With Intestinal Failure (SBS-IF)
- Short Bowel Syndrome
Approved drugs for the same conditions: Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Apraglutide" as an intervention, largest first.
- Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFPivotal-lookingCompleted
VectivBio AGIndustry
NCT04627025 · 164 participants · Start Jan 26, 2021 · Primary completion Jan 2, 2024
Drug: apraglutide · For: Short Bowel Syndrome
Sites: Los Angeles, California; Naples, Florida; Chicago, Illinois · 68 sites in all
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.Pivotal-lookingActive, not recruiting
VectivBio AGIndustry
NCT05018286 · 158 participants · Start Jul 13, 2021 · Primary completion Oct 30, 2027
Drug: Apraglutide · For: Short Bowel Syndrome
Sites: Los Angeles, California; Naples, Florida; Chicago, Illinois · 66 sites in all
- A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)Pivotal-lookingRecruiting
VectivBio AGIndustry
NCT07742735 · 124 participants (planned) · Start Aug 2026 · Primary completion Oct 2028
Drug: Apraglutide; Placebo · For: Short Bowel Syndrome (SBS); SBS Associated With Intestinal Failure (SBS-IF)
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 94 sites in all
VectivBio AGIndustry
NCT05995704 · 42 participants · Start Mar 2, 2023 · Primary completion Jul 24, 2023
Drug: Apraglutide; Placebo and 1 more · For: Healthy Subjects
Sites: Groningen, Netherlands
- Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference FormulationCompleted
VectivBio AGIndustry
NCT06002555 · 34 participants · Start May 23, 2023 · Primary completion Sep 22, 2023
Drug: Apraglutide · For: Healthy Subjects
Sites: Groningen, Netherlands
VectivBio AGIndustry
NCT05415410 · 31 participants · Start May 25, 2022 · Primary completion Dec 17, 2024
Drug: Apraglutide · For: GVHD
Sites: Stanford, California; Iowa City, Iowa; Boston, Massachusetts · 13 sites in all
VectivBio AGIndustry
NCT04699032 · 16 participants · Start Dec 8, 2020 · Primary completion Jul 5, 2021
Drug: Apraglutide · For: Chronic Kidney Disease
Sites: Orlando, Florida; Saint Paul, Minnesota
VectivBio AGIndustry
NCT05706623 · 16 participants · Start Jan 30, 2023 · Primary completion Apr 4, 2023
Drug: Apraglutide · For: Hepatic Impairment
Sites: Münich, Germany; Bratislava, Slovakia
VectivBio AGIndustry
NCT04964986 · 10 participants · Start Jun 14, 2021 · Primary completion Jun 6, 2023
Drug: Apraglutide · For: Short Bowel Syndrome
Sites: Leuven, Belgium; Clichy, France
GlyPharma TherapeuticsIndustry
NCT03417765 · 0 participants · Start Sep 1, 2018 · Primary completion Mar 31, 2019
Drug: FE 203799 · For: Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Hodgkin's, Adult
Newest research
PubMed records naming it or its code names, newest first.
- STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure.
Joly F, Vanuytsel T, Kirby DF, et al. · Clin Gastroenterol Hepatol 2026
- Pharmacological Strategies for Mitigating Cytarabine-Induced Multi-Organ Toxicity: A Scoping Review on Mechanisms, Efficacy and Clinical Implications.
Konstantinidis I, Tsokkou S, Makedou K, et al. · Cancers (Basel) 2026
- Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome.
Ekhlas D, Verbiest A, Stas M, et al. · Clin Nutr ESPEN 2026
- Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?
Gorard L, Boucher M, Rutter C · Curr Opin Gastroenterol 2026
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
Nordell P, Jansson-Löfmark R, Gennemark P · Clin Pharmacokinet 2026
- Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with intestinal failure: A systematic review and meta-analysis.
Bastas A, Williams K, Wong D · Clin Nutr ESPEN 2026
Also in development for Short Bowel Syndrome (SBS)
- GlepaglutideZP1848Phase 34 trials
Zealand Pharma · Short Bowel Syndrome, Short Bowel Syndrome (SBS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.